SourceOne Global Partners Launches New Omega-3 Formula
The company introduced LysOmega, a new supplement designed to improve fatty acid absorption in Las Vegas.
Updated on Oct. 26, 2026 in Alzheimer’s
Live Poll
Is now a good time to pay more for supplements promising better nutrient absorption?
SourceOne Global Partners debuted its LysOmega formula at the SupplySide Global 2026 event. The supplement combines DHA and EPA with phospholipids and choline to improve organ absorption.
Why it matters
The product addresses the difficulty of achieving optimal organ absorption of DHA and EPA. By targeting the blood-brain and blood-retina barriers, the supplement seeks to provide more effective delivery than standard formulations.
A Phase I study demonstrated that the VESIsorb delivery system increases omega-3 absorption by up to 26-fold. The system has 35 years of commercial use and relies on small droplet sizes to ensure bioavailability.
The players
SourceOne Global Partners
An organization focused on the development and commercialization of advanced nutritional ingredients and delivery technologies.
Michael Davidson
The researcher currently leading the upcoming clinical trial project to evaluate the formulation's performance.
The details
Developed over a four-year project, LysOmega utilizes the VESIsorb delivery system to ensure homogeneity and absorption. It is specifically formulated to transport fatty acids across the blood-brain and blood-retina barriers.
Timeline
October 26-30, 2026: SupplySide Global 2026 held in Las Vegas.
Q4 2026: Commencement of the planned human clinical trial.
The Big Picture
This development marks an expansion of the VESIsorb delivery system, which has been established for 35 years across various applications. It reflects a broader industry trend toward maximizing nutrient bioavailability to address specific physiological barriers.
The introduction of this supplement offers a new option for those looking to improve fatty acid intake for cognitive and eye health. Users may see this product enter the market following the successful completion of upcoming clinical trials.
The takeaway
This supplement highlights the importance of delivery mechanisms in how well the body absorbs essential nutrients. Consumers should monitor upcoming clinical trial results to understand the true effectiveness of these new formulations for long-term health.
What happens next
A human clinical trial is scheduled to commence in Q4 2026. This study will evaluate the supplement to determine if it produces higher and more consistent circulating DHA and EPA levels in participants.
Further reading
For more information on current brain health research and nutrient supplements, visit the Alzheimer’s section.
Source note: This article includes information reported by Nutritioninsight.
Live Poll
Is now a good time to pay more for supplements promising better nutrient absorption?
